Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease

Am J Hematol. 2017 Oct;92(10):E610-E611. doi: 10.1002/ajh.24850. Epub 2017 Jul 29.

Authors

James H Jerkins¹, Mehdi Hamadani^{1

2}, Felicia Zook¹, Narendranath Epperla¹, Bronwen E Shaw^{1

2}, Wael Saber^{1

2}, J Douglas Rizzo^{1

2}, Marcelo Pasquini^{1

2}, Saurabh Chhabra¹, William R Drobyski¹, Parameswaran N Hari^{1

2}, Nirav N Shah¹

Affiliations

¹ Medical College of Wisconsin, Blood and Marrow Transplant Program, Milwaukee, Wisconsin.
² Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin.

PMID: 28699171
DOI: 10.1002/ajh.24850

No abstract available

Publication types

Clinical Trial
Letter

MeSH terms

Acute Disease
Adult
Allografts
Disease-Free Survival
Gastrointestinal Diseases* / drug therapy
Gastrointestinal Diseases* / mortality
Graft vs Host Disease* / drug therapy
Graft vs Host Disease* / mortality
Hematologic Neoplasms / mortality
Hematologic Neoplasms / therapy
Humans
Male
Middle Aged
Peripheral Blood Stem Cell Transplantation
Survival Rate
alpha 1-Antitrypsin / administration & dosage*

Substances

SERPINA1 protein, human
alpha 1-Antitrypsin